How Glaucoma Is Treated: Eye Drops, Lasers & Surgery

Lowering the pressure inside the eye is the single proven way to slow glaucoma and protect the optic nerve from further damage. Glaucoma is a progressive condition driven largely by elevated intraocular pressure (IOP), which gradually destroys the nerve fibers that carry visual signals to the brain, causing irreversible vision loss. The treatments available today all aim at that same target, reducing IOP, but they do it through very different mechanisms and carry very different trade-offs. What starts as a once-daily eye drop can eventually involve laser procedures, microsurgical implants, or traditional filtering surgery, and understanding the full treatment ladder helps you make sense of the choices your ophthalmologist is weighing.

Why Lowering Eye Pressure Is the Goal

The eye constantly produces a clear fluid called aqueous humor, which nourishes internal structures and then drains out through a spongy tissue called the trabecular meshwork. When drainage slows or is partially blocked, fluid backs up and pressure climbs. That sustained pressure compresses and damages the optic nerve at the back of the eye. Once those nerve fibers die, the vision they served is gone for good.¹ Every current glaucoma treatment, whether a bottle of drops or an operating-room procedure, works by either reducing how much fluid the eye makes or improving how efficiently it drains out.

There is an important exception worth knowing early. Some people develop optic nerve damage even though their IOP measures in the statistically normal range, a condition called normal-tension glaucoma. Vascular factors, particularly poor regulation of blood flow to the optic nerve, appear to play a central role in these cases.² Even here, though, lowering IOP further remains the primary therapeutic strategy because clinical trials have shown it slows progression. Research into neuroprotective therapies that go beyond pressure reduction is active but still largely experimental.

Eye Drops and How They Work

Medicated eye drops remain the most common first-line treatment worldwide. Five broad classes of IOP-lowering drops exist, each acting through a different mechanism. The most widely prescribed are prostaglandin analogs such as latanoprost, bimatoprost, and travoprost. These work by remodeling the tissue in the drainage pathways of the eye, loosening the extracellular matrix and widening the spaces through which fluid can pass. The result is improved outflow and lower pressure.³ Prostaglandin analogs are popular because they need only one drop per day, usually at bedtime, and their systemic side effects are minimal. Local side effects can include darkening of the iris color, longer and thicker eyelashes, and mild redness.

Beta-blockers like timolol reduce IOP by decreasing fluid production inside the eye. They are effective but carry potentially serious systemic side effects because the drug can be absorbed into the bloodstream. People with asthma, certain heart conditions, or low blood pressure sometimes cannot use them safely. Alpha-2 agonists such as brimonidine also lower fluid production and modestly increase outflow, but they can cause allergic reactions and drowsiness. Carbonic anhydrase inhibitors, available as both drops and oral tablets, slow fluid production through a different enzyme pathway. The oral form, acetazolamide, can cause tingling in the fingers, fatigue, and kidney stones, so it is generally reserved for acute pressure spikes or cases where drops alone are insufficient.

The newest class of drops targets a pathway called Rho-kinase. These ROCK inhibitors, such as netarsudil, work directly on the cells of the trabecular meshwork, relaxing them so that the drainage tissue opens up and fluid flows out more freely.⁴ Laboratory studies show that ROCK inhibitors can actually reverse some of the stiffening and scarring changes in the meshwork that contribute to glaucoma in the first place, widening the drainage tissue and reducing local adhesion of the cells lining it.⁵ The most common side effect is conjunctival redness, which can be cosmetically bothersome but is not dangerous. Combination drops that pair a ROCK inhibitor with a prostaglandin analog in a single bottle are now available, which helps simplify the regimen for people who need more than one class of medication.

The Real-World Problem With Eye Drops

On paper, drops work well. In practice, getting people to use them consistently is one of the biggest challenges in glaucoma care. A cross-sectional survey found that forgetfulness was the strongest predictor of non-adherence, with roughly a fivefold increase in odds of poor compliance. Difficulty instilling drops and problems with the medication schedule also contributed meaningfully.⁶ About a quarter of patients in that study reported trouble with aim when applying drops, and nearly one in five had difficulty controlling how many drops came out of the bottle. These are not trivial complaints for a condition that demands daily treatment for life. Higher medication cost, lower health literacy, and the sheer burden of complex regimens all further erode adherence.⁷

Drop instillation aids, essentially small plastic devices that help you aim the bottle and squeeze it steadily, are underused but appear to help. In one study comparing three different aids, over 60% of patients found the devices helpful and said they would consider using them long-term.⁸ If you struggle with drops, it is worth asking your eye doctor about these. They are inexpensive and widely available.

Beyond adherence, the drops themselves can cause ocular surface problems over time. Most glaucoma drops contain a preservative called benzalkonium chloride (BAK), which keeps the solution sterile but damages corneal and conjunctival cells with chronic exposure.⁹ Long-term BAK exposure can trigger chronic inflammation, worsen dry-eye symptoms, and even harm the trabecular meshwork tissue that the drops are trying to protect. Perhaps most concerning, chronic BAK-related damage to the conjunctiva can compromise the success of filtration surgery later on, because the inflammatory changes promote scarring around the surgical site.¹⁰ Preservative-free formulations are increasingly available and are worth requesting if you are on multiple drops or have signs of ocular surface disease. Minimizing BAK exposure improves outcomes across the board.¹¹

Laser Treatments

Laser therapy occupies a middle ground between drops and incisional surgery. The most commonly used procedure is selective laser trabeculoplasty, or SLT. During SLT, short pulses of laser light are applied to the trabecular meshwork through a special lens placed on the eye. The laser energy triggers a biological response, likely involving localized inflammation and immune-cell recruitment, that remodels the drainage tissue and improves fluid outflow.¹² The procedure takes a few minutes in the clinic, requires only numbing drops, and has a relatively gentle side-effect profile. Some patients experience temporary redness, mild soreness, or a brief pressure spike afterward.

A meta-analysis comparing SLT as a first-line treatment against topical medications in newly diagnosed open-angle glaucoma found no significant difference in IOP reduction between the two approaches, but the SLT group needed fewer medications, had lower rates of subsequent glaucoma surgery, and experienced fewer ocular side effects.¹³ That evidence has shifted practice in many countries: rather than being seen as a backup when drops fail, SLT is increasingly offered as a reasonable starting treatment. It can be repeated if the effect wears off over time, though the durability of each treatment varies from person to person.

A different laser procedure, laser peripheral iridotomy (LPI), is used specifically for angle-closure glaucoma and eyes at risk for it. In angle-closure, the iris physically blocks the drainage angle. LPI creates a tiny hole in the peripheral iris that allows fluid to flow freely from behind the iris into the front chamber, eliminating the blockage and widening the drainage angle.¹⁴ It is usually a preventive measure, performed before a full angle-closure attack occurs, and is quick and effective.

For eyes with severe or refractory glaucoma where other treatments have failed, cyclophotocoagulation uses laser energy directed through the white of the eye to partially destroy the ciliary body, the tissue that produces aqueous humor.¹⁵ By reducing fluid production at the source, this procedure lowers pressure even in eyes that do not respond well to drainage-enhancing treatments. It carries a higher risk of complications, including chronic inflammation and over-treatment leading to dangerously low pressure, so it is typically reserved for advanced cases or eyes with poor visual potential.

Traditional Glaucoma Surgery

When drops and laser are not enough, incisional surgery comes into play. Trabeculectomy remains the gold standard. The surgeon creates a small flap in the sclera (the white outer coat of the eye) that allows aqueous humor to drain out of the eye and collect under the conjunctiva in a small blister-like pocket called a filtering bleb. From there, the fluid is absorbed into surrounding blood vessels. The procedure can achieve substantial pressure reduction, with post-operative IOP commonly reaching the low teens or even single digits in millimeters of mercury.

The Achilles’ heel of trabeculectomy is scarring. The body’s wound-healing response can seal the drainage pathway shut, and roughly 30% of trabeculectomies fail within three years, with nearly half failing by five years.¹⁶ To counteract this, surgeons routinely apply anti-scarring agents during the procedure. Mitomycin C, a chemotherapy-derived drug, is applied briefly to the tissue at the surgical site to inhibit the fibroblasts responsible for scar formation.¹⁷ Research in animal models has confirmed that even low doses of mitomycin C promote looser collagen deposition, prolong bleb survival, and sustain lower IOP.¹⁸ Five-fluorouracil is another anti-scarring option, sometimes injected in the post-operative period if signs of scarring appear. The use of these agents has significantly improved long-term success rates but introduces its own risks, including thin, fragile blebs that can leak or become infected.

Glaucoma drainage implants, sometimes called tube shunts, offer an alternative when trabeculectomy has failed or is unlikely to succeed. These devices consist of a small silicone tube placed into the front chamber of the eye, connected to a plate sutured behind the eye. Fluid travels through the tube to the plate, where a fibrous capsule forms and absorbs it. Non-restrictive designs like the Baerveldt implant rely entirely on the capsule’s resistance to regulate flow, while the Ahmed Glaucoma Valve incorporates a flow-restricting mechanism to reduce the risk of dangerously low pressure in the early post-operative period.¹⁹ These implants have become a critical tool for refractory glaucoma, particularly in eyes with extensive prior surgery, inflammation, or neovascular disease where trabeculectomy has a high failure rate.

Minimally Invasive Glaucoma Surgery

Over the past decade, a newer category called minimally invasive glaucoma surgery, or MIGS, has carved out space between laser and traditional surgery. MIGS procedures use tiny devices or micro-incisions, typically placed through the inside of the eye during a combined cataract-and-glaucoma operation. Because they involve minimal tissue disruption, MIGS devices offer faster recovery and a more favorable safety profile than trabeculectomy or tube shunts.²⁰ They are best suited for patients with mild to moderate open-angle glaucoma who want to reduce or eliminate their drop burden.

The trade-off is that MIGS generally produces more modest pressure reduction than traditional surgery. Trabeculectomy can bring IOP down to 11 to 13 mmHg, while most MIGS devices leave pressure somewhat higher.²¹ For someone with advanced glaucoma who needs very low pressures to prevent further vision loss, a MIGS device alone may not be enough. But for someone with earlier disease and a moderate medication burden, the balance of safety and efficacy can be attractive. The most commonly used MIGS devices target Schlemm’s canal, the main drainage channel. Examples include the iStent, a tiny titanium stent that bypasses the trabecular meshwork, and the Hydrus, a scaffold that dilates a portion of the canal. Other MIGS approaches create a new drainage pathway into the space under the conjunctiva, which generally achieves lower pressures but with a slightly higher complication rate than canal-based devices.

Sustained-Release Implants and the Future of Drop-Free Treatment

The adherence and surface-toxicity problems with daily eye drops have spurred the development of sustained-release drug delivery systems designed to bypass the drop bottle entirely. These range from intracameral implants, tiny biodegradable devices placed inside the eye during a brief procedure, to punctal plugs loaded with medication and contact lenses engineered to slowly release drugs. The goal is consistent, patient-independent IOP control over weeks or months from a single administration.²²

Intracameral prostaglandin implants are the most advanced in this category. Both bimatoprost and travoprost sustained-release implants have been studied in clinical trials, and a meta-analysis found that both provide durable IOP reduction while substantially decreasing the need for topical drops.²³ The bimatoprost implant (Durysta) is already approved in the United States, and the travoprost implant is under regulatory review. These implants dissolve over several months, after which re-administration may be needed. Early experience suggests they are particularly useful for patients who cannot manage drops due to physical limitations or cognitive decline, and for anyone whose ocular surface has been damaged by years of preserved drops.²⁴

The Burden of Living With Glaucoma

Treatment decisions in glaucoma happen against a backdrop of significant personal and financial cost. A large assessment of the health and economic burden of glaucoma found that people with the condition were more than three times as likely to have fallen in the prior year and more than six times as likely to have been involved in a motor vehicle collision in the prior five years compared with controls who had similar systemic health conditions.²⁵ Those numbers underscore that glaucoma is not just an abstract optic-nerve disease. It erodes functional vision in ways that affect daily safety. Financially, direct ophthalmology-related costs climbed roughly fourfold as disease severity advanced from the earliest stage to end-stage disease or blindness, reflecting the escalating intensity of treatment needed as the disease worsens.

This is a practical reason to treat glaucoma aggressively and early, even when you feel fine. By the time you notice vision loss, substantial irreversible damage has already occurred. The initial investment in drops, laser, or surgery is far less burdensome than the cumulative cost of advanced disease, both in dollars and in quality of life.

Neuroprotection and Gene Therapy on the Horizon

Everything described so far targets IOP. The next frontier in glaucoma treatment is neuroprotection: directly shielding the optic nerve cells, called retinal ganglion cells, from damage independent of what the pressure is doing. This would be a genuine paradigm shift, particularly for people with normal-tension glaucoma or those whose nerve damage progresses despite well-controlled pressure.

One promising avenue involves gene therapy. In animal models of glaucoma, researchers delivered a gene encoding nerve growth factor (NGF) directly to retinal ganglion cells using a viral vector. The treatment preserved ganglion cell density, maintained the integrity of the nerve fiber layer, and kept the cells functioning across multiple glaucoma models, without triggering detectable immune responses or damaging the retina.²⁶ This is still preclinical work, not yet tested in human trials, but the results are encouraging enough that the research community is actively pursuing translational paths. Other neuroprotective strategies under investigation include drugs that block specific cell-death pathways, antioxidants targeting mitochondrial dysfunction, and growth factors delivered through various platforms.

Smart Contact Lenses and Continuous Monitoring

One of the longstanding gaps in glaucoma care is that IOP is usually measured only during office visits, a few times a year. Yet eye pressure fluctuates throughout the day and night, and those fluctuations may matter for disease progression. A single snapshot measurement in the clinic can miss spikes that happen at 3 a.m. Smart contact lenses equipped with miniature pressure sensors are being developed to fill this gap. These devices can monitor IOP continuously and transmit real-time data to clinicians, capturing the kind of pressure profile that office visits simply cannot.²⁷ Some prototypes are also designed to deliver medication on demand in response to detected pressure changes, combining monitoring and treatment in one wearable device. While no such lens is in routine clinical use yet, several are in advanced development and clinical testing. If they prove reliable, they could fundamentally change how treatment is titrated, moving from fixed dosing schedules to responsive, individualized therapy based on actual pressure data collected around the clock.